Triomics nabs $22M to bring oncology-specific AI to cancer centers

Triomics, a startup specializing in AI-powered oncology tools, has raised $22 million in Series B funding. The round was led by Battery Ventures, with participation from Nexus Venture Partners, Lightspeed, and Y Combinator. Founded in 2021, Triomics initially focused on helping oncologists identify suitable clinical trials for patients but expanded its platform to include verifiable patient summaries and automation of administrative tasks. The company’s AI models are trained specifically on oncology data, distinguishing it from generic AI agents. This specialization has earned adoption from leading institutions like Memorial Sloan Kettering and Yale Cancer Center. Triomics automates data-heavy tasks such as reviewing thousands of pages of medical records—including physician notes, imaging reports, and faxes—and generating concise summaries for clinicians. Beyond clinical trial matching, Triomics reduces appointment prep time by surfacing key patient information within existing clinical tools, allowing oncologists to spend more time with patients. The platform also automates the submission of tumor reports to government registries, fulfilling a legal mandate for cancer centers. Competitors like Abridge and Microsoft’s Nuance focus on AI medical scribes for documenting patient-doctor conversations, but Triomics targets administrative inefficiencies in oncology workflows. The company reported a fourfold increase in enterprise customers over the past year, driving a tenfold rise in annualized recurring revenue. Triomics’ growth reflects the broader challenge of managing dense, multi-year medical records in oncology, where patient histories are complex and staff burnout is common. By streamlining administrative tasks, the startup aims to improve efficiency and patient care in cancer centers.